This inventor holds 1 USPTO granted patent. Top assignee: Ligand Pharmaceuticals, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Marc Van Dijk: Innovator in Antibody Development
Introduction
Marc Van Dijk is a notable inventor based in Bosch En Duin, US. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. His work has led to advancements that may have a profound impact on medical treatments.
Latest Patents
Marc Van Dijk holds a patent for "ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF." This patent represents his innovative approach to antibody development, which could play a crucial role in therapeutic applications.
Career Highlights
He is currently employed at Ligand Pharmaceuticals, Inc., where he continues to push the boundaries of scientific research and innovation. His expertise in antibody technology has positioned him as a key player in the biotechnology sector.
Collaborations
Marc has collaborated with esteemed colleagues such as Cornelia Anne Mundt and Gerd Ritter. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Marc Van Dijk's contributions to the field of biotechnology, particularly through his patent on anti-CTLA-4 antibodies, highlight his role as an innovator. His work at Ligand Pharmaceuticals, Inc. and collaborations with other experts further underscore his impact on the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile